$7.8M Financing Boosts NRx's Expansion with Kadima Institute Acquisition for PTSD and Depression Care: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
Summary
Neuroplastic treatments represent a rapidly emerging class of interventions that cause the growth of new connections (synapses) between brain cells that have been shown in multiple clinical trials to relieve symptoms of depression and suicidality. HOPEs parent company,, is currently applying to the FDA for approval of intravenous preservative-free ketamine to treat suicidal depression.On May 13announced signing of a definitive agreement to purchase the Kadima Neuropsychiatry Institute. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Spravato, transcranial magnetic stimulation ("TMS") as well as medication management. Dr. Feifel will joinHOPE as its first Chief Medical Innovation Officer upon closing of the acquisition.On May 5announced the filing of a patent application for NRX-100, its preservative-free intravenous ketamine formulation for the treatment of suicidal depression. The NDA filing is anticipated by the end of the second quarter of this year (Q2 2025).notes recent statements by the Secretary of Health and Human Services supporting the importance of psychedelic drugs to treat severe depression and PTSD.